Recovery and Survival of All Patients with Narsoplimab for NASDAQ:OMER by AlenCiken

Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome

-- All six patients, requiring mechanical ventilation prior to treatment, recovered, survived and were discharged from the hospital

-- Narsoplimab treatment was associated with rapid and sustained improvement across all assessed markers of endothelial/cellular damage and/or inflammation

-- Omeros is in discussions with U.S. government agencies regarding acceleration of narsoplimab manufacturing for use in COVID-19 patients

Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.